Eli Lilly Receivables 2010-2024 | LLY

Eli Lilly receivables from 2010 to 2024. Receivables can be defined as the total amount of collectibles for a company
  • Eli Lilly receivables for the quarter ending September 30, 2024 were $12.052B, a 16.29% increase year-over-year.
  • Eli Lilly receivables for 2023 were $11.336B, a 32.45% increase from 2022.
  • Eli Lilly receivables for 2022 were $8.559B, a 5.31% increase from 2021.
  • Eli Lilly receivables for 2021 were $8.127B, a 17.29% increase from 2020.
Eli Lilly Annual Receivables
(Millions of US $)
2023 $11,336
2022 $8,559
2021 $8,127
2020 $6,929
2019 $5,542
2018 $5,777
2017 $5,262
2016 $4,766
2015 $4,072
2014 $3,801
2013 $4,023
2012 $3,888
2011 $4,238
2010 $4,158
2009 $3,832
Eli Lilly Quarterly Receivables
(Millions of US $)
2024-09-30 $12,052
2024-06-30 $13,079
2024-03-31 $10,014
2023-12-31 $11,336
2023-09-30 $10,364
2023-06-30 $9,171
2023-03-31 $9,022
2022-12-31 $8,559
2022-09-30 $8,325
2022-06-30 $7,672
2022-03-31 $7,806
2021-12-31 $8,127
2021-09-30 $7,025
2021-06-30 $6,903
2021-03-31 $6,659
2020-12-31 $6,929
2020-09-30 $5,845
2020-06-30 $5,776
2020-03-31 $6,353
2019-12-31 $5,542
2019-09-30 $5,538
2019-06-30 $5,590
2019-03-31 $5,178
2018-12-31 $5,777
2018-09-30 $5,653
2018-06-30 $5,579
2018-03-31 $5,271
2017-12-31 $5,262
2017-09-30 $5,015
2017-06-30 $4,956
2017-03-31 $4,614
2016-12-31 $4,766
2016-09-30 $4,521
2016-06-30 $4,493
2016-03-31 $4,187
2015-12-31 $4,072
2015-09-30 $4,068
2015-06-30 $4,097
2015-03-31 $3,826
2014-12-31 $3,801
2014-09-30 $3,635
2014-06-30 $3,754
2014-03-31 $3,746
2013-12-31 $4,023
2013-09-30 $3,995
2013-06-30 $4,214
2013-03-31 $4,029
2012-12-31 $3,888
2012-09-30 $3,796
2012-06-30 $3,772
2012-03-31 $3,931
2011-12-31 $4,238
2011-09-30 $4,098
2011-06-30 $4,447
2011-03-31 $4,183
2010-12-31 $4,158
2010-09-30 $3,875
2010-06-30 $3,653
2010-03-31 $3,730
2009-12-31 $3,832
2009-09-30 $3,483
2009-06-30 $3,330
2009-03-31 $3,160
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $789.394B $34.124B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Novo Nordisk (NVO) Denmark $481.063B 34.69
Johnson & Johnson (JNJ) United States $374.313B 15.18
AbbVie (ABBV) United States $352.544B 18.56
Merck (MRK) United States $260.350B 17.30
Novartis AG (NVS) Switzerland $217.584B 14.46
AstraZeneca (AZN) United Kingdom $199.957B 17.81
Pfizer (PFE) United States $151.422B 10.36
Sanofi (SNY) $130.241B 11.80
Innoviva (INVA) United States $1.263B 10.51